Report cover image

Global Infantile Spasms Therapeutics Market Outlook and Growth Opportunities 2025

Publisher APO Research, Inc.
Published Jul 16, 2025
Length 196 Pages
SKU # APRC20280468

Description

Summary

According to APO Research, the global Infantile Spasms Therapeutics market is projected to grow from US$ million in 2025 to US$ million by 2031, at a compound annual growth rate (CAGR) of % during the forecast period.

The North American market for Infantile Spasms Therapeutics is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % from 2025 through 2031.

The Asia-Pacific market for Infantile Spasms Therapeutics is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

In China, the Infantile Spasms Therapeutics market is expected to rise from $ million to $ million by 2031, at a CAGR of I% from 2025 through 2031.

The Europe market for Infantile Spasms Therapeutics is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Major global companies in the Infantile Spasms Therapeutics market include Valerion Therapeutics, Retrophin, Orphelia Pharma, Mallinckrodt, Insys Therapeutics, H. Lundbeck, GW Pharmaceuticals, Catalyst Pharmaceuticals and Anavex Life Sciences, etc. In 2024, the top three vendors accounted for approximately % of the market revenue.

This report presents an overview of global market for Infantile Spasms Therapeutics, revenue and gross margin. Analyses of the global market trends, with historic market revenue for 2020 - 2024, estimates for 2025, and projections of CAGR through 2031.

This report researches the key producers of Infantile Spasms Therapeutics, also provides the value of main regions and countries. Of the upcoming market potential for Infantile Spasms Therapeutics, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Infantile Spasms Therapeutics revenue, market share and industry ranking of main companies, data from 2020 to 2025. Identification of the major stakeholders in the global Infantile Spasms Therapeutics market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
All companies have demonstrated varying levels of sales growth and profitability over the past six years, while some companies have experienced consistent growth, others have shown fluctuations in performance. The overall trend suggests a positive outlook for the global Infantile Spasms Therapeutics company landscape, with companies adapting to market dynamics and maintaining profitability amidst changing conditions.
Infantile Spasms Therapeutics Segment by Company

Valerion Therapeutics
Retrophin
Orphelia Pharma
Mallinckrodt
Insys Therapeutics
H. Lundbeck
GW Pharmaceuticals
Catalyst Pharmaceuticals
Anavex Life Sciences
Infantile Spasms Therapeutics Segment by Type

Oral
Injection
Infantile Spasms Therapeutics Segment by Application

Hospital
Clinic
Other
Infantile Spasms Therapeutics Segment by Region

North America

United States
Canada
Europe

Germany
France
U.K.
Italy
Netherlands
Nordic Countries
Asia-Pacific

China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America

Mexico
Brazil
Argentina
Middle East & Africa

Turkey
Saudi Arabia
UAE

Study Objectives

1. To analyze and research the global Infantile Spasms Therapeutics status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.
2. To present the Infantile Spasms Therapeutics key companies, revenue, market share, and recent developments.
3. To split the Infantile Spasms Therapeutics breakdown data by regions, type, companies, and application.
4. To analyze the global and key regions Infantile Spasms Therapeutics market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify Infantile Spasms Therapeutics significant trends, drivers, influence factors in global and regions.
6. To analyze Infantile Spasms Therapeutics competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Infantile Spasms Therapeutics market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Infantile Spasms Therapeutics and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Infantile Spasms Therapeutics.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.
Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Infantile Spasms Therapeutics industry.
Chapter 3: Detailed analysis of Infantile Spasms Therapeutics company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales value of Infantile Spasms Therapeutics in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.
Chapter 7: Sales value of Infantile Spasms Therapeutics in country level. It provides sigmate data by type, and by application for each country/region.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 9: Concluding Insights.

Please Note: Single-User license will be delivered via PDF from the publisher without the rights to print or to edit.

Table of Contents

196 Pages
1 Market Overview
1.1 Product Definition
1.2 Global Infantile Spasms Therapeutics Market Size, 2020 VS 2024 VS 2031
1.3 Global Infantile Spasms Therapeutics Market Size (2020-2031)
1.4 Assumptions and Limitations
1.5 Study Goals and Objectives
2 Infantile Spasms Therapeutics Market Dynamics
2.1 Infantile Spasms Therapeutics Industry Trends
2.2 Infantile Spasms Therapeutics Industry Drivers
2.3 Infantile Spasms Therapeutics Industry Opportunities and Challenges
2.4 Infantile Spasms Therapeutics Industry Restraints
3 Infantile Spasms Therapeutics Market by Company
3.1 Global Infantile Spasms Therapeutics Company Revenue Ranking in 2024
3.2 Global Infantile Spasms Therapeutics Revenue by Company (2020-2025)
3.3 Global Infantile Spasms Therapeutics Company Ranking (2023-2025)
3.4 Global Infantile Spasms Therapeutics Company Manufacturing Base and Headquarters
3.5 Global Infantile Spasms Therapeutics Company Product Type and Application
3.6 Global Infantile Spasms Therapeutics Company Establishment Date
3.7 Market Competitive Analysis
3.7.1 Global Infantile Spasms Therapeutics Market Concentration Ratio (CR5 and HHI)
3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2024
3.7.3 2024 Infantile Spasms Therapeutics Tier 1, Tier 2, and Tier 3 Companies
3.8 Mergers and Acquisitions Expansion
4 Infantile Spasms Therapeutics Market by Type
4.1 Infantile Spasms Therapeutics Type Introduction
4.1.1 Oral
4.1.2 Injection
4.2 Global Infantile Spasms Therapeutics Sales Value by Type
4.2.1 Global Infantile Spasms Therapeutics Sales Value by Type (2020 VS 2024 VS 2031)
4.2.2 Global Infantile Spasms Therapeutics Sales Value by Type (2020-2031)
4.2.3 Global Infantile Spasms Therapeutics Sales Value Share by Type (2020-2031)
5 Infantile Spasms Therapeutics Market by Application
5.1 Infantile Spasms Therapeutics Application Introduction
5.1.1 Hospital
5.1.2 Clinic
5.1.3 Other
5.2 Global Infantile Spasms Therapeutics Sales Value by Application
5.2.1 Global Infantile Spasms Therapeutics Sales Value by Application (2020 VS 2024 VS 2031)
5.2.2 Global Infantile Spasms Therapeutics Sales Value by Application (2020-2031)
5.2.3 Global Infantile Spasms Therapeutics Sales Value Share by Application (2020-2031)
6 Infantile Spasms Therapeutics Regional Value Analysis
6.1 Global Infantile Spasms Therapeutics Sales Value by Region: 2020 VS 2024 VS 2031
6.2 Global Infantile Spasms Therapeutics Sales Value by Region (2020-2031)
6.2.1 Global Infantile Spasms Therapeutics Sales Value by Region: 2020-2025
6.2.2 Global Infantile Spasms Therapeutics Sales Value by Region (2026-2031)
6.3 North America
6.3.1 North America Infantile Spasms Therapeutics Sales Value (2020-2031)
6.3.2 North America Infantile Spasms Therapeutics Sales Value Share by Country, 2024 VS 2031
6.4 Europe
6.4.1 Europe Infantile Spasms Therapeutics Sales Value (2020-2031)
6.4.2 Europe Infantile Spasms Therapeutics Sales Value Share by Country, 2024 VS 2031
6.5 Asia-Pacific
6.5.1 Asia-Pacific Infantile Spasms Therapeutics Sales Value (2020-2031)
6.5.2 Asia-Pacific Infantile Spasms Therapeutics Sales Value Share by Country, 2024 VS 2031
6.6 South America
6.6.1 South America Infantile Spasms Therapeutics Sales Value (2020-2031)
6.6.2 South America Infantile Spasms Therapeutics Sales Value Share by Country, 2024 VS 2031
6.7 Middle East & Africa
6.7.1 Middle East & Africa Infantile Spasms Therapeutics Sales Value (2020-2031)
6.7.2 Middle East & Africa Infantile Spasms Therapeutics Sales Value Share by Country, 2024 VS 2031
7 Infantile Spasms Therapeutics Country-level Value Analysis
7.1 Global Infantile Spasms Therapeutics Sales Value by Country: 2020 VS 2024 VS 2031
7.2 Global Infantile Spasms Therapeutics Sales Value by Country (2020-2031)
7.2.1 Global Infantile Spasms Therapeutics Sales Value by Country (2020-2025)
7.2.2 Global Infantile Spasms Therapeutics Sales Value by Country (2026-2031)
7.3 USA
7.3.1 USA Infantile Spasms Therapeutics Sales Value Growth Rate (2020-2031)
7.3.2 USA Infantile Spasms Therapeutics Sales Value Share by Type, 2024 VS 2031
7.3.3 USA Infantile Spasms Therapeutics Sales Value Share by Application, 2024 VS 2031
7.4 Canada
7.4.1 Canada Infantile Spasms Therapeutics Sales Value Growth Rate (2020-2031)
7.4.2 Canada Infantile Spasms Therapeutics Sales Value Share by Type, 2024 VS 2031
7.4.3 Canada Infantile Spasms Therapeutics Sales Value Share by Application, 2024 VS 2031
7.5 Mexico
7.5.1 Mexico Infantile Spasms Therapeutics Sales Value Growth Rate (2020-2031)
7.5.2 Mexico Infantile Spasms Therapeutics Sales Value Share by Type, 2024 VS 2031
7.5.3 Mexico Infantile Spasms Therapeutics Sales Value Share by Application, 2024 VS 2031
7.6 Germany
7.6.1 Germany Infantile Spasms Therapeutics Sales Value Growth Rate (2020-2031)
7.6.2 Germany Infantile Spasms Therapeutics Sales Value Share by Type, 2024 VS 2031
7.6.3 Germany Infantile Spasms Therapeutics Sales Value Share by Application, 2024 VS 2031
7.7 France
7.7.1 France Infantile Spasms Therapeutics Sales Value Growth Rate (2020-2031)
7.7.2 France Infantile Spasms Therapeutics Sales Value Share by Type, 2024 VS 2031
7.7.3 France Infantile Spasms Therapeutics Sales Value Share by Application, 2024 VS 2031
7.8 U.K.
7.8.1 U.K. Infantile Spasms Therapeutics Sales Value Growth Rate (2020-2031)
7.8.2 U.K. Infantile Spasms Therapeutics Sales Value Share by Type, 2024 VS 2031
7.8.3 U.K. Infantile Spasms Therapeutics Sales Value Share by Application, 2024 VS 2031
7.9 Italy
7.9.1 Italy Infantile Spasms Therapeutics Sales Value Growth Rate (2020-2031)
7.9.2 Italy Infantile Spasms Therapeutics Sales Value Share by Type, 2024 VS 2031
7.9.3 Italy Infantile Spasms Therapeutics Sales Value Share by Application, 2024 VS 2031
7.10 Spain
7.10.1 Spain Infantile Spasms Therapeutics Sales Value Growth Rate (2020-2031)
7.10.2 Spain Infantile Spasms Therapeutics Sales Value Share by Type, 2024 VS 2031
7.10.3 Spain Infantile Spasms Therapeutics Sales Value Share by Application, 2024 VS 2031
7.11 Russia
7.11.1 Russia Infantile Spasms Therapeutics Sales Value Growth Rate (2020-2031)
7.11.2 Russia Infantile Spasms Therapeutics Sales Value Share by Type, 2024 VS 2031
7.11.3 Russia Infantile Spasms Therapeutics Sales Value Share by Application, 2024 VS 2031
7.12 Netherlands
7.12.1 Netherlands Infantile Spasms Therapeutics Sales Value Growth Rate (2020-2031)
7.12.2 Netherlands Infantile Spasms Therapeutics Sales Value Share by Type, 2024 VS 2031
7.12.3 Netherlands Infantile Spasms Therapeutics Sales Value Share by Application, 2024 VS 2031
7.13 Nordic Countries
7.13.1 Nordic Countries Infantile Spasms Therapeutics Sales Value Growth Rate (2020-2031)
7.13.2 Nordic Countries Infantile Spasms Therapeutics Sales Value Share by Type, 2024 VS 2031
7.13.3 Nordic Countries Infantile Spasms Therapeutics Sales Value Share by Application, 2024 VS 2031
7.14 China
7.14.1 China Infantile Spasms Therapeutics Sales Value Growth Rate (2020-2031)
7.14.2 China Infantile Spasms Therapeutics Sales Value Share by Type, 2024 VS 2031
7.14.3 China Infantile Spasms Therapeutics Sales Value Share by Application, 2024 VS 2031
7.15 Japan
7.15.1 Japan Infantile Spasms Therapeutics Sales Value Growth Rate (2020-2031)
7.15.2 Japan Infantile Spasms Therapeutics Sales Value Share by Type, 2024 VS 2031
7.15.3 Japan Infantile Spasms Therapeutics Sales Value Share by Application, 2024 VS 2031
7.16 South Korea
7.16.1 South Korea Infantile Spasms Therapeutics Sales Value Growth Rate (2020-2031)
7.16.2 South Korea Infantile Spasms Therapeutics Sales Value Share by Type, 2024 VS 2031
7.16.3 South Korea Infantile Spasms Therapeutics Sales Value Share by Application, 2024 VS 2031
7.17 India
7.17.1 India Infantile Spasms Therapeutics Sales Value Growth Rate (2020-2031)
7.17.2 India Infantile Spasms Therapeutics Sales Value Share by Type, 2024 VS 2031
7.17.3 India Infantile Spasms Therapeutics Sales Value Share by Application, 2024 VS 2031
7.18 Australia
7.18.1 Australia Infantile Spasms Therapeutics Sales Value Growth Rate (2020-2031)
7.18.2 Australia Infantile Spasms Therapeutics Sales Value Share by Type, 2024 VS 2031
7.18.3 Australia Infantile Spasms Therapeutics Sales Value Share by Application, 2024 VS 2031
7.19 Southeast Asia
7.19.1 Southeast Asia Infantile Spasms Therapeutics Sales Value Growth Rate (2020-2031)
7.19.2 Southeast Asia Infantile Spasms Therapeutics Sales Value Share by Type, 2024 VS 2031
7.19.3 Southeast Asia Infantile Spasms Therapeutics Sales Value Share by Application, 2024 VS 2031
7.20 Brazil
7.20.1 Brazil Infantile Spasms Therapeutics Sales Value Growth Rate (2020-2031)
7.20.2 Brazil Infantile Spasms Therapeutics Sales Value Share by Type, 2024 VS 2031
7.20.3 Brazil Infantile Spasms Therapeutics Sales Value Share by Application, 2024 VS 2031
7.21 Argentina
7.21.1 Argentina Infantile Spasms Therapeutics Sales Value Growth Rate (2020-2031)
7.21.2 Argentina Infantile Spasms Therapeutics Sales Value Share by Type, 2024 VS 2031
7.21.3 Argentina Infantile Spasms Therapeutics Sales Value Share by Application, 2024 VS 2031
7.22 Chile
7.22.1 Chile Infantile Spasms Therapeutics Sales Value Growth Rate (2020-2031)
7.22.2 Chile Infantile Spasms Therapeutics Sales Value Share by Type, 2024 VS 2031
7.22.3 Chile Infantile Spasms Therapeutics Sales Value Share by Application, 2024 VS 2031
7.23 Colombia
7.23.1 Colombia Infantile Spasms Therapeutics Sales Value Growth Rate (2020-2031)
7.23.2 Colombia Infantile Spasms Therapeutics Sales Value Share by Type, 2024 VS 2031
7.23.3 Colombia Infantile Spasms Therapeutics Sales Value Share by Application, 2024 VS 2031
7.24 Peru
7.24.1 Peru Infantile Spasms Therapeutics Sales Value Growth Rate (2020-2031)
7.24.2 Peru Infantile Spasms Therapeutics Sales Value Share by Type, 2024 VS 2031
7.24.3 Peru Infantile Spasms Therapeutics Sales Value Share by Application, 2024 VS 2031
7.25 Saudi Arabia
7.25.1 Saudi Arabia Infantile Spasms Therapeutics Sales Value Growth Rate (2020-2031)
7.25.2 Saudi Arabia Infantile Spasms Therapeutics Sales Value Share by Type, 2024 VS 2031
7.25.3 Saudi Arabia Infantile Spasms Therapeutics Sales Value Share by Application, 2024 VS 2031
7.26 Israel
7.26.1 Israel Infantile Spasms Therapeutics Sales Value Growth Rate (2020-2031)
7.26.2 Israel Infantile Spasms Therapeutics Sales Value Share by Type, 2024 VS 2031
7.26.3 Israel Infantile Spasms Therapeutics Sales Value Share by Application, 2024 VS 2031
7.27 UAE
7.27.1 UAE Infantile Spasms Therapeutics Sales Value Growth Rate (2020-2031)
7.27.2 UAE Infantile Spasms Therapeutics Sales Value Share by Type, 2024 VS 2031
7.27.3 UAE Infantile Spasms Therapeutics Sales Value Share by Application, 2024 VS 2031
7.28 Turkey
7.28.1 Turkey Infantile Spasms Therapeutics Sales Value Growth Rate (2020-2031)
7.28.2 Turkey Infantile Spasms Therapeutics Sales Value Share by Type, 2024 VS 2031
7.28.3 Turkey Infantile Spasms Therapeutics Sales Value Share by Application, 2024 VS 2031
7.29 Iran
7.29.1 Iran Infantile Spasms Therapeutics Sales Value Growth Rate (2020-2031)
7.29.2 Iran Infantile Spasms Therapeutics Sales Value Share by Type, 2024 VS 2031
7.29.3 Iran Infantile Spasms Therapeutics Sales Value Share by Application, 2024 VS 2031
7.30 Egypt
7.30.1 Egypt Infantile Spasms Therapeutics Sales Value Growth Rate (2020-2031)
7.30.2 Egypt Infantile Spasms Therapeutics Sales Value Share by Type, 2024 VS 2031
7.30.3 Egypt Infantile Spasms Therapeutics Sales Value Share by Application, 2024 VS 2031
8 Company Profiles
8.1 Valerion Therapeutics
8.1.1 Valerion Therapeutics Comapny Information
8.1.2 Valerion Therapeutics Business Overview
8.1.3 Valerion Therapeutics Infantile Spasms Therapeutics Revenue and Gross Margin (2020-2025)
8.1.4 Valerion Therapeutics Infantile Spasms Therapeutics Product Portfolio
8.1.5 Valerion Therapeutics Recent Developments
8.2 Retrophin
8.2.1 Retrophin Comapny Information
8.2.2 Retrophin Business Overview
8.2.3 Retrophin Infantile Spasms Therapeutics Revenue and Gross Margin (2020-2025)
8.2.4 Retrophin Infantile Spasms Therapeutics Product Portfolio
8.2.5 Retrophin Recent Developments
8.3 Orphelia Pharma
8.3.1 Orphelia Pharma Comapny Information
8.3.2 Orphelia Pharma Business Overview
8.3.3 Orphelia Pharma Infantile Spasms Therapeutics Revenue and Gross Margin (2020-2025)
8.3.4 Orphelia Pharma Infantile Spasms Therapeutics Product Portfolio
8.3.5 Orphelia Pharma Recent Developments
8.4 Mallinckrodt
8.4.1 Mallinckrodt Comapny Information
8.4.2 Mallinckrodt Business Overview
8.4.3 Mallinckrodt Infantile Spasms Therapeutics Revenue and Gross Margin (2020-2025)
8.4.4 Mallinckrodt Infantile Spasms Therapeutics Product Portfolio
8.4.5 Mallinckrodt Recent Developments
8.5 Insys Therapeutics
8.5.1 Insys Therapeutics Comapny Information
8.5.2 Insys Therapeutics Business Overview
8.5.3 Insys Therapeutics Infantile Spasms Therapeutics Revenue and Gross Margin (2020-2025)
8.5.4 Insys Therapeutics Infantile Spasms Therapeutics Product Portfolio
8.5.5 Insys Therapeutics Recent Developments
8.6 H. Lundbeck
8.6.1 H. Lundbeck Comapny Information
8.6.2 H. Lundbeck Business Overview
8.6.3 H. Lundbeck Infantile Spasms Therapeutics Revenue and Gross Margin (2020-2025)
8.6.4 H. Lundbeck Infantile Spasms Therapeutics Product Portfolio
8.6.5 H. Lundbeck Recent Developments
8.7 GW Pharmaceuticals
8.7.1 GW Pharmaceuticals Comapny Information
8.7.2 GW Pharmaceuticals Business Overview
8.7.3 GW Pharmaceuticals Infantile Spasms Therapeutics Revenue and Gross Margin (2020-2025)
8.7.4 GW Pharmaceuticals Infantile Spasms Therapeutics Product Portfolio
8.7.5 GW Pharmaceuticals Recent Developments
8.8 Catalyst Pharmaceuticals
8.8.1 Catalyst Pharmaceuticals Comapny Information
8.8.2 Catalyst Pharmaceuticals Business Overview
8.8.3 Catalyst Pharmaceuticals Infantile Spasms Therapeutics Revenue and Gross Margin (2020-2025)
8.8.4 Catalyst Pharmaceuticals Infantile Spasms Therapeutics Product Portfolio
8.8.5 Catalyst Pharmaceuticals Recent Developments
8.9 Anavex Life Sciences
8.9.1 Anavex Life Sciences Comapny Information
8.9.2 Anavex Life Sciences Business Overview
8.9.3 Anavex Life Sciences Infantile Spasms Therapeutics Revenue and Gross Margin (2020-2025)
8.9.4 Anavex Life Sciences Infantile Spasms Therapeutics Product Portfolio
8.9.5 Anavex Life Sciences Recent Developments
9 Concluding Insights
10 Appendix
10.1 Reasons for Doing This Study
10.2 Research Methodology
10.3 Research Process
10.4 Authors List of This Report
10.5 Data Source
10.5.1 Secondary Sources
10.5.2 Primary Sources
How Do Licenses Work?
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.